Molecular Cancer Therapeutics · 2013 · 61 citations · 31 references
The epithelial-mesenchymal transition (EMT) is a process associated with the metastasis of solid tumors as well as with the acquisition of resistance to standard anticancer modalities. A major initiator of EMT in carcinoma cells is TGF-β, which has been shown to induce the expression of several transcription factors ultimately responsible for initiating and maintaining the EMT program. We have previously identified Brachyury, a T-box transcription factor, as an inducer of mesenchymal features in human carcinoma cells. In this study, a potential link between Brachyury and TGF-β signaling has been investigated. The results show for the first time that Brachyury expression is enhanced during TGF-β1-induced EMT in various human cancer cell lines, and that a positive feedback loop is established between Brachyury and TGF-β1 in mesenchymal-like tumor cells. In this context, Brachyury overexpression is shown to promote upregulation of TGF-β1 at the mRNA and protein levels, an effect mediated by activation of the TGF-β1 promoter in the presence of high levels of Brachyury. Furthermore, inhibition of TGF-β1 signaling by a small-molecule inhibitor of TGF-β receptor type I decreases Brachyury expression, induces a mesenchymal-to-epithelial transition, and renders cancer cells more susceptible to chemotherapy. This study thus has implications for the future development of clinical trials using TGF-β inhibitors in combination with other anticancer agents.
31
Activation of the interferon system by short-interfering RNAs
Carol A. Sledz, Michelle Holko, Michael J. de Veer et al. · Nature Cell Biology · 2003 · 1.4K citations
Molecular Definition of Breast Tumor Heterogeneity
Michail Shipitsin, Lauren L. Campbell, Pedram Argani et al. · Cancer Cell · 2007 · 1.4K citations · Full text
Disease Heterogeneity, Breast Oncology, Tumor Heterogeneity +6